The Discipline of Pharmacology and Chemical Biology is one of the earliest doctoral degree awarding points in China, and it is also the first batch of China clinical pharmacology research bases. Established by and under the guidance of a group of highly respected senior researchers such as Professor Jin Zhengjun, the scale of Discipline of Pharmacology and Chemical Biology has gradually expended and the academic level is continuously improved. It is listed in the China National “211 Project” and “985 Project” and Shanghai Key Subject of “Double First Class”and "Local High-Level Construction Project". The ESI of "Pharmacology and Toxicology" ranks the top 1‰in the world.

The Discipline adheres to the strategy of Talent First with Fostering Talents from Inside as well as Introducing Talents from Outside. A large number of outstanding young teachers and scientific researching academics stand out, forming a harmonious, energetic and cohesive innovation team. During the development process, the Discipline continuously attracts and fosters excellent talents, creating innovative talented people in the atmosphere of paying equal attention to scientific research and teaching, and gradually forms a cultural of “Aggregation, Adaptability, Openness, and Win-Win”. The Discipline has established close academic and personnel exchanging and cooperation relationships with University of Toronto, University of Minnesota, Monash University, Paris Descartes University, Paris Diderot University – Paris 7 and Claude Bernard University Lyon 1, etc., and is constantly improving the academic competitiveness and internationalization level.

The discipline currently has a total of 36 personnel, including 27 senior titles, including 10 PI researchers. There are 1 member from the China State Council Discipline Review Group, 2 members from National High-level Talent Plan, 3 members from National High-level Youth Talent Plan, 2 Outstanding Young Fund winners of the National Natural Science Foundation of China, 3 Shanghai Outstanding Academic Leaders, 2 Shanghai High-level Talent Program, 2 Shanghai High-level Youth Talent Program, 4 members from Shanghai Science and Technology Development Funds, 2 members from Shanghai Pujiang Talent Plan, 3 members from Shanghai Dawn Program, 1 nomination of Shanghai Health System Silver Snake Award and 1 prize-winner of Shanghai Labor Medal, etc.

The subject aims at the frontier fields of biomedicine and national scientific and technological strategy needs to carry out pharmacology, chemical biology, nano drug delivery and translational medical research, mainly including the discovery of new targets for neurodegenerative diseases, tumors and cardio-cerebrovascular diseases and the development of innovative drugs, drug power research on pharmacology and drug metabolomics, chemical biology research based on disease functional genomics information and clinical transformation of new drugs and innovative biotechnology for the prevention and treatment of major chronic diseases. In the past five years, the Discipline has presided over 1 major project of the Ministry of Science and Technology, 3 sub-projects of the national key research and Development Plan of the Ministry of Science and Technology , 1 key special project of the Ministry of Science and Technology, 52 national, municipal, university-level and horizontal projects under research. It has published more than 200 papers in internationally high-profile journals such as Nature Medinice, Nature Communication, Cell Metabolism, PNAS, Advanced Science, ACS nano, Nano Letters, etc. Among them, the latest research achievements in 2022 have been published in Cancer Research, Biomaterials, Advanced Materials, APSB, Nature Cell Biology and other international high-level journals. 10 invention patents have been applied for and 4 of them have been authorized. There are two incubation and transformation programs, one Alzheimer's disease intervention and new therapy program undergoing I/IIa clinical trials, two innovative preparation technology platforms selected into the innovation achievement incubation programs, and one original anti-tumor new drug program cooperated with Fudan University. The scientific research achievements win the First Prize of Science and Technology Progress of Ministry of Education, the First Prize of Shanghai Science and Technology Progress Award, the Second Prize of Natural Science of Ministry of Education, the First Prize of Shanghai Medical Science and Technology Award, the Second Prize of Chinese Medical Science and Technology and the Second Prize of Science and Technology Award of Chinese Pharmaceutical Association. It has two researching new drugs with independent intellectual property rights of the national "New Major Drug Creation".

The Discipline of Pharmacology and Chemical Biology supports Shanghai Collaborative Innovation Center for Translational Medicine, Phase I Clinical Pharmacokinetics Laboratory of the National Drug Clinical Trial Institute, Pharmacokinetics and Pharmacokinetics Laboratory of the New Neuropsychiatric Drug GCP Platform of the Ministry of Science and Technology, and Shanghai University System Pharmacology Key Laboratory etc. The subject has multiple experimental platforms, including molecular imaging platforms, composed of confocal microscopes, fluorescent microscopes, etc., to meet the needs of analyzing cellular images at various levels; pharmacokinetic and metabolomics platforms, consisting of multiple ultra-high performance liquid phases Chromatography tandem triple quadrupole mass spectrometry and high-resolution mass spectrometry can be used to complete clinical pharmacokinetics, metabolomics, lipidomics and other analytical experiments; animal behavioral experiment platform is composed of water maze, open field and other behavioral instruments and The analysis software and other components can complete the experiments of animal learning and memory, emotion and sports behavior analysis; The small animal imaging platform is composed of a fully automatic brain stereo positioning system and small animal PET / CT, etc., which provides a guarantee for the use of animal models for research; drug target discovery and new drug screening platform, by BIACORE molecular interaction, ITC isothermal titration The instrument, Flexstation III calcium flow analyzer, PHERAstar, FDSS high-speed imaging analyzer, etc., provide sufficient conditions for the development and verification of new targets and high-throughput screening and activity determination at the molecular and cellular levels; Chemoinformatics and Bioinformatics Platform is composed of a central randomization system, an electronic data collection and query management system, and a statistical analysis system，it realizes more efficient and convenient resource sharing of data, calculations, and graphics, and facilitates the process of information processing; nanobiology platform consists of nanometer biology related equipment such as particle size analyzer and ultracentrifuge system, which provides the conditions for carrying out nanobiology research. The above experimental platforms are managed and operated by professional technicians to ensure the smooth development of scientific research.